Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions

(2022) Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions. Cellular & molecular biology letters. p. 63. ISSN 1689-1392 (Electronic) 1425-8153 (Print) 1425-8153 (Linking)

Full text not available from this repository.

Abstract

The pandemic outbreak of coronavirus disease 2019 (COVID-19) has created health challenges in all parts of the world. Understanding the entry mechanism of this virus into host cells is essential for effective treatment of COVID-19 disease. This virus can bind to various cell surface molecules or receptors, such as angiotensin-converting enzyme 2 (ACE2), to gain cell entry. Respiratory failure and pulmonary edema are the most important causes of mortality from COVID-19 infections. Cytokines, especially proinflammatory cytokines, are the main mediators of these complications. For normal respiratory function, a healthy air-blood barrier and sufficient blood flow to the lungs are required. In this review, we first discuss airway epithelial cells, airway stem cells, and the expression of COVID-19 receptors in the airway epithelium. Then, we discuss the suggested molecular mechanisms of endothelial dysfunction and blood vessel damage in COVID-19. Coagulopathy can be caused by platelet activation leading to clots, which restrict blood flow to the lungs and lead to respiratory failure. Finally, we present an overview of the effects of immune and non-immune cells and cytokines in COVID-19-related respiratory failure.

Item Type: Article
Keywords: *covid-19 Cytokines Humans Peptidyl-Dipeptidase A *Respiratory Insufficiency SARS-CoV-2 Airway epithelial cells Covid-19 Endothelial cells Platelets Pulmonary edema SARS-CoV-2 Advisory Boards: Transdermal Cap Inc., Cleveland, OH Hologenix Inc. Santa Monica, CA Vielight, Toronto, Canada JOOVV Inc., Minneapolis-St. Paul MN Consulting USHIO Corp, Japan Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. Stockholding: Niraxx Light Therapeutics, Inc., Irvine CA JelikaLite Corp., New York NY. The other authors declare no conflicts of interest.
Page Range: p. 63
Journal or Publication Title: Cellular & molecular biology letters
Journal Index: Pubmed
Volume: 27
Number: 1
Identification Number: https://doi.org/10.1186/s11658-022-00363-3
ISSN: 1689-1392 (Electronic) 1425-8153 (Print) 1425-8153 (Linking)
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/24485

Actions (login required)

View Item View Item